MoonLake Immunotherapeutics Overview
MoonLake Immunotherapeutics Target Price
Analysts' 12-month price predictions for MLTX.
Get informed when a big investor buys or sells
+ FollowShare Price
$18.27
Average Target Price
$40.00
118.9% upside
118.9% upside2 analysts in the last 4 months
High: $45 | Low: $35
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-11 | H.C. Wainwright | $45 | 146.3% upside |  |
| 2026-02-24 | Oppenheimer | $35 | 91.6% upside | |
| 2026-01-14 | Goldman Sachs | $10 |  45.3% downside | |
| 2026-01-09 | H.C. Wainwright | $32 | 75.2% upside | |
| 2026-01-09 | UBS | $24 | 31.4% upside | |
| 2026-01-08 | UBS | $45 | 146.3% upside | |
| 2025-11-21 | H.C. Wainwright | $26 | 42.3% upside | |
| 2025-11-06 | Oppenheimer | $30 | 64.2% upside | |
| 2025-11-03 | H.C. WainwrightRaghuram Selvaraju | $30 | 64.2% upside | |
| 2025-10-07 | Oppenheimer | $25 | 36.8% upside | |
| 2025-09-30 | Goldman Sachs | $7 | 61.7% downside | |
| 2025-09-30 | NeedhamSerge Belanger | $20 | 9.5% upside | |
| 2025-09-30 | Guggenheim | $20 | 9.5% upside | |
| 2025-09-29 | Jefferies | $8 | 56.2% downside | |
| 2025-09-29 | RBC Capital | $10 | 45.3% downside | |
| 2025-03-18 | RBC Capital | $67 | 266.7% upside | |
| 2024-07-01 | H.C. WainwrightRaghuram Selvaraju | $100 | 447.3% upside | |
| 2024-04-02 | Goldman SachsRichard Law | $62 | 239.4% upside | |
| 2023-08-31 | NeedhamSerge Belanger | $76 | 316% upside | |